CCM-3 Anti-Human 100 µg

In stock

Cat-Nr.
102-PA27S
Size
100 µg
  €190.00

Description / CCM-3

Cerebral cavernous malformations (CCMs) are sporadically acquired or inherited vascular lesions of the central nervous system consisting of clusters of dilated thin-walled blood vessels that predispose individuals to seizures and stroke. Mutations in CCM1, CCM2, or CCM3 lead to cerebral cavernous malformations, one of the most common hereditary vascular diseases of the brain. Endothelial cells within these lesions are the main disease compartments. Here, we show that adenoviral CCM3 expression inhibits endothelial cell migration, proliferation, and tube formation while down regulation of endogenous CCM3 results in increased formation of tube-like structures. Adenoviral CCM3 expression does not induce apoptosis under normal endothelial cell culture conditions but protects endothelial cells from staurosporine-induced cell death. Tyrosine kinase activity profiling suggests that CCM3 supports PDPK-1/Akt-mediated endothelial cell quiescence and survival (Schleider et al, Neurogenetics 12, 2011).

More Information

Size 100 µg
Source Rabbit
Biological Activity Western Blot: Use 1-5 µg/ml
Clone Nr. Rabbit IgG
Species Reactivity Human
Formulation lyophilized
Buffer 0.5X PBS, pH 7.2
Reconstitution Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
Stability and Storage The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50%
Antigen Recombinant human CCM3 (RT #300-056)
Application WB, IF
Synonyms PDCD10; CCM3; TFAR15; programmed cell death 10
Uniprot ID Q9BUL8
Protein RefSeq NP_009148.2
mRNA RefSeq NM_007217.3

All prices plus VAT + possible delivery charges